CC
SRPT icon

Casdin Capital’s Sarepta Therapeutics SRPT Stock Holding History

Casdin Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.45M Buy
+470,000
New +$8.89M 0.42% 29
2025
Q3 		– Sell
-990,097
Closed -$16.9M – 37
2025
Q2 		$16.9M Buy
990,097
+89,314
+10% +$3.81M 1.54% 14
2025
Q1 		$57.5M Sell
900,783
-172,717
-16% -$18.2M 4.7% 6
2024
Q4 		$131M Hold
1,073,500
– – 8.69% 4
2024
Q3 		$134M Hold
1,073,500
– – 8.94% 5
2024
Q2 		$170M Buy
1,073,500
+4,500
+0.4% +$578K 12.95% 3
2024
Q1 		$138M Buy
1,069,000
+62,500
+6% +$7.66M 10.29% 4
2023
Q4 		$97.1M Sell
1,006,500
-3,830
-0.4% -$367K 9.53% 3
2023
Q3 		$122M Sell
1,010,330
-4,670
-0.5% -$528K 13.55% 1
2023
Q2 		$116M Sell
1,015,000
-145,000
-13% -$18.7M 10.16% 2
2023
Q1 		$160M Sell
1,160,000
-155,000
-12% -$20.1M 13.17% 2
2022
Q4 		$170M Buy
1,315,000
+90,000
+7% +$10.4M 13.2% 1
2022
Q3 		$135M Buy
1,225,000
+575,000
+88% +$58M 8.9% 3
2022
Q2 		$48.7M Sell
650,000
-150,000
-19% -$11M 4.12% 9
2022
Q1 		$62.5M Sell
800,000
-550,000
-41% -$42.1M 2.8% 14
2021
Q4 		$122M Buy
1,350,000
+250,000
+23% +$21.4M 3.43% 12
2021
Q3 		$102M Buy
1,100,000
+215,000
+24% +$16.6M 2.53% 13
2021
Q2 		$68.8M Buy
885,000
+335,000
+61% +$25.4M 1.75% 20
2021
Q1 		$41M Buy
550,000
+20,000
+4% +$1.85M 1.22% 23
2020
Q4 		$90.4M Hold
530,000
– – 2.68% 13
2020
Q3 		$74.4M Hold
530,000
– – 3.33% 9
2020
Q2 		$85M Sell
530,000
-140,000
-21% -$19.1M 5.03% 4
2020
Q1 		$65.5M Hold
670,000
– – 6.96% 2
2019
Q4 		$86.5M Sell
670,000
-210,000
-24% -$21.2M 7.95% 1
2019
Q3 		$66.3M Buy
880,000
+545,000
+163% +$64.4M 6.86% 5
2019
Q2 		$50.9M Buy
335,000
+30,000
+10% +$3.65M 4.76% 8
2019
Q1 		$36.4M Buy
305,000
+155,000
+103% +$19.9M 3.99% 13
2018
Q4 		$16.4M Buy
150,000
+110,000
+275% +$13.8M 2.8% 16
2018
Q3 		$6.46M Buy
+40,000
New +$5.47M 0.79% 29

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Casdin Capital's SRPT Position: Q2 2026 in Review

Casdin Capital opened a new position in Sarepta Therapeutics (SRPT) in Q2 2026: 470,000 shares worth $8.45M. The stake represents 0.42% of the portfolio and ranks #29 among its holdings. This is a return to the name: Casdin Capital previously reported a position in SRPT as recently as Q2 2025.

Casdin Capital first reported a position in SRPT in Q3 2018 and has held it in 29 quarters since. The position peaked at $170M in Q4 2022. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Casdin Capital held 470,000 shares of Sarepta Therapeutics worth $8.45M as of Q2 2026.
  • Sarepta Therapeutics was a new Casdin Capital position in Q2 2026.
  • Sarepta Therapeutics made up 0.42% of Casdin Capital's portfolio in Q2 2026, its #29 holding.
  • Casdin Capital first reported a position in Sarepta Therapeutics in Q3 2018 and has held it in 29 quarters since.
  • Casdin Capital's Sarepta Therapeutics position peaked at $170M in Q4 2022.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Casdin Capital's 13F filing for Q2 2026, filed 14 Aug 2026.